|
|
 |
|
Viewing report
|
|
|
|
Drugs of Tomorrow 2001: Cancer Overview
Datamonitor, March 2001
Drugs of Tomorrow 2001: Cancer Overview provides a comprehensive analysis of the current cancer market. The report focuses on the oncology market as a whole, looking at growth factors, class dominance and R&D focus. An in-depth analysis of the cancer pipeline by disease target examines current drugs in development and the key investors in the area for the principal tumor types (breast, brain, colorectal, head and neck, leukemia, lung, ovarian, pancreatic and prostate cancers). areas, with increasing year-on-year sales, the oncology market is becoming an increasingly important area for focus within the pharmaceutical sector. Whilst oncology does not represent the largest segment of the global pharmaceutical market, increasing incidence of the disease, combined with significant sales potential for drugs indicated for cancer ensures that it remains one of the most attractive areas for R&D investment. Cancer offers rich rewards for new and developing therapies,
Customers who bought this item also bought
Drugs of Tomorrow: Cancer Overview
Drugs of Tomorrow: Cancer Overview - The synergistic advance: innovatives compliment traditional chemotherapies
Drugs of Tomorrow 2002: Colorectal Cancer
Drugs of Tomorrow 2000: Prostate Cancer - Hormonals and Beyond
Pipeline Insight: Cancer Overview - Increasing Collaboration to Accommodate Increasing Fragmentation
Pipeline Insight: Cancer Overview - Increasing Collaboration to Accommodate Increasing Fragmentation
Drugs of Tommorow 2002: Breast Cancer
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
The Cancer Market Outlook to 2012
Pipeline Insight: Prostate Cancer - Domination By The Innovative Classes
Cancer Therapeutics - Market Insight and R&D Pipeline Analysis
|
|
|
|
